Cell Surface News Today

and a special sunday edition of the velshi banned book club brings us a beautiful, lyrical story of love and identity, a novel about mexican born texas raised gay teens that well feel universal when you read it. my conversation with the author, who will discover the secrets of the universe, its one that you will not want to miss. velshi starts next. >> good morning to you, i am ali velshi, sunday, october 2nd. we have reached a new phase in the ever winding investigation into the insur...

With the popular culture that informs and shapes us, perhaps even more than the great books of history, perhaps even more than our denominational religions, it’s worth pointing out the

 Company AnnouncementTEPKINLY® (epcoritamab) is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapyConditional marketing authorization approval from the Eur...

TEPKINLY® is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of...

Company Announcement TEPKINLY® is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma ...

Company Announcement The positive CHMP opinion is supported by results from the EPCORE™ NHL-1 phase 1/2 trial evaluating the preliminary efficacy and...

COPENHAGEN, Denmark--(BUSINESS WIRE)--Jul 21, 2023--

/PRNewswire/ -- The "Cell Surface Markers: Global Strategic Business Report" report has been added to ResearchAndMarkets.coms offering. Global Cell Surface...

Four oral presentations presented at ASH highlight data evaluating investigational epcoritamab for the treatment of relapsed/refractory (R/R) foll...

COPENHAGEN, Denmark--(BUSINESS WIRE)--Epcoritamab featured in multiple data disclosures, including four oral presentationsResults presented from the phase 1b/2 EPCORE™ NHL-2 trial of epcoritamab combined with standard salvage therapy in patients with transplant eligible relapsed/refractory (R/R) diffuse large B-cell...